Stockreport

Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)

GEMPHIRE THERAPEUTICS INC COMMON  (GEMP) 
Last gemphire therapeutics inc common earnings: 5/9 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.gemphire.com
PDF Pediatric NAFLD/NASH is a large and untreated market; provides an opportunity to advance gemcabene in an underserved area with millions of affected patients Proof-of-co [Read more]